Chiasma sinks after FDA requests new Mycapssa trial

Chiasma Inc. (NASDAQ:CHMA) plummeted $6.42 (63%) to $3.75 on Monday after it said FDA wants another trial of acromegaly candidate Mycapssa octreotide. The company disclosed

Read the full 254 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE